Fwd: Rudolph's perplexing legacy - Herald Tribune

---------- Forwarded message ----------
From: asbestos cancer - Live Search News <rssfwd@rssfwd.com>
Date: Sun, Jun 8, 2008 at 10:31 PM
Subject: Rudolph's perplexing legacy - Herald Tribune
To: mesothelioma77@gmail.com


SARASOTA — Paul Rudolph came to Sarasota in 1948 as a young architect with a master's degree from Harvard and left 10 years later to become dean of the School of Art and Architecture at Yale. From that influential post he became the most ...

Sun, 08 Jun 2008 13:53:00 GMT

___
Source: http://www.heraldtribune.com/article/20080608/NEWS/223993615/0/newssitemap
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Benefit small from lung cancer screening method (Reuters via Yahoo! News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Benefit small from lung cancer screening method (Reuters via Yahoo! News)
To: mesothelioma77@gmail.com


A high-tech X-ray called a spiral CT scan may help reduce lung cancer deaths in smokers and former smokers, but only reduces their overall risk of premature death by 4 percent, researchers reported on Tuesday.

Tue, 10 Jun 2008 21:28:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=128df378m/*http%3A//news.yahoo.com/s/nm/20080610/hl_nm/cancer_lung_screening_dc_1
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Jun 10;
Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, Cortinovis D, Conte GD, Ceribelli A, Bearz A, Salamina S, De Vincenzo F, Cappuzzo F, Marangolo M, Torri V, Santoro A

The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. In this study, pooled data from two phase II trials of pemetrexed and carboplatin (PC) as first-line therapy were retrospectively analysed for comparisons between age groups. Patients received pemetrexed 500 mg m(-2) and carboplatin AUC 5 mg ml(-1) min(-1) intravenously every 21 days with standard vitamin supplementation. Elderly patients were defined as those >/=70 years old. A total of 178 patients with an ECOG performance status of /=70 years (27%). Grade 3-4 haematological toxicity was slightly worse in >/=70 vs

___
Source: http://www.hubmed.org/display.cgi?uids=18542071
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

[

Fwd: Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Jun 10;
Sørensen JB, Frank H, Palshof T

The aim was to evaluate the activity of cisplatin and vinorelbine in previously untreated, inoperable patients having histologically verified malignant pleural mesothelioma (MPM), normal organ function, and performance status 0-2. Treatment was vinorelbine 25 mg m(-2) i.v. weekly and cisplatin 100 mg m(-2) i.v. every 4 weeks with hydration and standard prophylactic antiemetic treatment. Patients gave written informed consent. Characteristics of 54 consecutive patients were: males 85%, epithelial subtype 74%, IMIG stages III and IV 35 and 46%, performance status 0, 1, and 2, 26, 69, and 6%, and median age 63 years (31-78 years). CTC grade 3 or 4 toxicity occurred with respect to leukocytopenia (48% of patients, grade 4 in 13%), nausea (13%), neurotoxicity (11%), nephrotoxicity (4%), and other toxicities (9%). There were no toxic deaths. The median number of cycles was four. The fraction of patients alive at 1-, 2-, and 3-years were 61, 31, and 4%, respectively, and median survival and median time to progression were 16.8 months (0.5 to 46.4 +months) and 7.2 months (1.6 to 40.6 + months). There were two CRs and 14 PRs (response rate 29.6%). Cisplatin and intravenous vinorelbine is a highly active regimen in MPM with a response rate and survival comparable to the most active regimens so far reported.British Journal of Cancer advance online publication, 10 June 2008; doi:10.1038/sj.bjc.6604421 www.bjcancer.com.



___
Source: http://www.hubmed.org/display.cgi?uids=18542078
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
To: mesothelioma77@gmail.com


[1]Cancer. 2008 Jun 9;
Hainsworth JD, Spigel DR, Barton J, Farley C, Schreeder M, Hon J, Greco FA

BACKGROUND.: The purpose of the current study was to evaluate the efficacy and toxicity of weekly bortezomib in the treatment of patients with recurrent/refractory multiple myeloma. METHODS.: A total of 40 patients with multiple myeloma who had received either 1 or 2 previous treatment regimens were treated with bortezomib at a dose of 1.6 mg/m(2) intravenously for 4 consecutive weeks, followed by 1 week without treatment. Responses were measured using International Myeloma Working Group criteria. RESULTS.: Twenty-two patients (55%; 95% confidence interval, 40%-70%) achieved objective responses to treatment, with a median response duration of 16 months. The median progression-free survival for all patients was 9.6 months, with a 1-year progression-free survival rate of 39%. The 1-year and 2-year overall survival rates were 75% and 51%, respectively. Weekly bortezomib was generally well tolerated; grade 3/4 (using the National Cancer Institute Common Toxicity Criteria [version 3.0]) neutropenia (13%), thrombocytopenia (20%), fatigue (15%), diarrhea (13%), and neuropathy (10%) were experienced by a minority of patients. CONCLUSIONS.: In the current study, a schedule of weekly bortezomib was found to be effective and well tolerated in patients with previously treated multiple myeloma. Although the response rate and duration appear comparable to those achieved with twice-weekly bortezomib, the relative efficacy of these 2 schedules cannot be determined definitively on the basis of this phase 2 study. A weekly schedule of bortezomib is a reasonable option for patients who have logistic difficulties receiving a twice-weekly schedule, and is an attractive schedule for incorporation into combination regimens. Cancer 2008. (c) 2008 American Cancer Society.



___
Source: http://www.hubmed.org/display.cgi?uids=18543319
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Is there an optimal comorbidity index for prostate cancer?

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Is there an optimal comorbidity index for prostate cancer?
To: mesothelioma77@gmail.com


[1]Cancer. 2008 Jun 9;
Cai T, Bartoletti R





___
Source: http://www.hubmed.org/display.cgi?uids=18543325
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Metastatic breast cancer cells colonize and degrade three-dimensional osteoblastic tissue in vitro.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Metastatic breast cancer cells colonize and degrade three-dimensional osteoblastic tissue in vitro.
To: mesothelioma77@gmail.com


[1]Clin Exp Metastasis. 2008 Jun 10;
Dhurjati R, Krishnan V, Shuman LA, Mastro AM, Vogler EA

Metastatic breast cancer cells (BCs) colonize a mineralized three-dimensional (3D) osteoblastic tissue (OT) grown from isolated pre-osteoblasts for up to 5 months in a specialized bioreactor. Sequential stages of BC interaction with OT include BC adhesion, penetration, colony formation, and OT reorganization into "Indian files" paralleling BC colonies, heretofore observed only in authentic pathological cancer tissue. BCs permeabilize OT by degrading the extra-cellular collagenous matrix (ECM) in which the osteoblasts are embedded. OT maturity (characterized by culture age and cell phenotype) profoundly affects the patterns of BC colonization. BCs rapidly form colonies on immature OT (higher cell/ECM ratio, osteoblastic phenotype) but fail to completely penetrate OT. By contrast, BCs efficiently penetrate mature OT (lower cell/ECM ratio, osteocytic phenotype) and reorganize OT. BC colonization provokes a strong osteoblast inflammatory response marked by increased expression of the pro-inflammatory cytokine IL-6. Furthermore, BCs inhibit osteoblastic bone formation by down-regulating synthesis of collagen and osteocalcin. Results strongly suggest that breast cancer disrupts the process of osteoblastic bone formation, in addition to upregulating osteoclastic bone resorption as widely reported. These observations may help explain why administration of bisphosphonates to humans with osteolytic metastases slows lesion progression by inhibiting osteoclasts but does not bring about osteoblast-mediated healing.



___
Source: http://www.hubmed.org/display.cgi?uids=18543066
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: The Nottingham Prognostic Index for Invasive Carcinoma of the Breast.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: The Nottingham Prognostic Index for Invasive Carcinoma of the Breast.
To: mesothelioma77@gmail.com


[1]Pathol Oncol Res. 2008 Jun 10;
Lee AH, Ellis IO

A useful prognostic factor in breast cancer has key roles, including identification of a group of patients whose prognosis is so good they do not require further treatment, such as adjuvant systemic therapy, after local surgery, and secondly a group with a poor prognosis for whom additional treatment would be appropriate. To be of clinical use, prognostic factors must show a wide separation in the outcome of the groups identified and select adequate numbers in each group. No single prognostic factor in invasive carcinoma of the breast satisfies all these criteria. However, the Nottingham prognostic index (NPI), which combines nodal status, tumour size and histological grade, does satisfy these criteria. The NPI has been validated by further studies in Nottingham and by studies in several other countries. Predictive factors, such as oestrogen receptor and HER-2 status, predict whether a tumour is likely to respond to a treatment, and are complimentary to prognostic factors. The NPI can be used in combination with predictive factors to select patients for systemic adjuvant treatments. There is the potential to improve the NPI by inclusion of other factors, such as vascular invasion, but any such alterations would require further validation.



___
Source: http://www.hubmed.org/display.cgi?uids=18543079
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Physical activity as a negative modulator of estrogen-induced breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Physical activity as a negative modulator of estrogen-induced breast cancer.
To: mesothelioma77@gmail.com


[1]Cancer Causes Control. 2008 Jun 10;
Coyle YM

Physical activity is a protective factor for breast cancer. Exposure to estrogen is an important determinant of breast cancer risk and exercise reduces estrogen levels, with the level of evidence being stronger for post-menopausal women. Possible mechanisms for estrogen induced breast cancer include increased breast epithelial cell proliferation, the metabolism of estrogen to genotoxic metabolites, such as DNA-adducts, and the silencing of tumor suppressor genes (TSGs) that have been implicated in breast carcinogenesis by inducing gene promoter hypermethylation, which is potentially reversible. Animal studies suggest that physical activity decreases breast tumor growth by promoting changes in cellular proliferation and apoptosis. Human studies provide some support for exercise producing favorable changes in estrogen metabolism that may lead to reduced breast epithelial cell proliferation. No studies have been performed to determine whether exercise decreases the accumulation of estrogen metabolite DNA-adducts in breast tissue. However, research supports the hypothesis that physical activity reduces promoter hypermethylation of TSGs implicated in breast carcinogenesis by lowering circulating estrogen levels. Thus, further research is necessary to clarify the mechanisms that relate to physical activity as a negative modulator of breast cancer risk to develop meaningful guidelines for the use of physical activity in breast cancer prevention.



___
Source: http://www.hubmed.org/display.cgi?uids=18543069
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc